HEALTH

Metabolife introduces two-stage program, online support services

BY Michael Johnsen

NEW YORK Metabolife is making its way back to retail shelves with a new two-stage supplement program and online support services. The program includes the newly reformulated flagship Metabolife Ultra and four other products to help support weight-management efforts.

“Metabolife is all new and features a revolutionary two-stage, easy-to-manage program that includes five products, new services, new packaging, a new Web site, and an online community support system to help people lose weight and maintain success,” stated Niki Simoneaux, director of brand marketing for Metabolife.

Stage one products include Metabolife Ultra, a formula that helps burn fat, curb hunger and boost energy; Metabolife Caffeine Free, to help reduce body fat and curb appetite without caffeine; and Metabolife Green Tea, which provides the added health benefits of green tea extract.

The second stage of the Metabolife program includes two new products, Metabolife Break Through and Metabolife Extreme Energy. Metabolife Break Through is a new patent-pending nutritional supplement containing a proprietary combination of nutrients shown to maintain full metabolic effect for at least eight weeks after initial weight loss, helping counteract the body’s natural tendency to keep unhealthy fat. Metabolife Extreme Energy contains a proprietary blend of Guarana extract, Asian ginseng extract, Green tea extract, Yerba Mate extract, Eleuthero extract, Rhodiola extract and Theanine that work together to help increase energy, improve mental alertness and increase metabolism.

Metabolife’s other new product, AquaSlim, is a ready-to-drink formulation with CitriMax and 148 mg of calcium per serving.In support of the new products, packaging and program, Metabolife is launching an advertising campaign entitled “You Deserve” that includes broadcast, print and online executions as part of an extensive re-branding effort.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

J&J posts record sales for Q1

BY Drew Buono

NEW BRUNSWICK, N.J. Johnson & Johnson released its first quarter 2008 sales results and it showed that the company had record sales for the quarter of $16.2 billion. This was a 7.7 percent increase as compared to the first quarter of 2007. Net earnings for the quarter were $3.6 billion.

Sales growth reflects the strong performance of Remicade, a biologic approved for the treatment of a number of immune mediated inflammatory diseases, which increased by 12.7 percent; and Concerta, a treatment for attention deficit hyperactivity disorder, which increased by 12 percent.

Sales though were also negatively affected by the proton pump inhibitor Aciphex, which saw sales decline by 27 percent, the pain patch Duragesic which fell by 35.3 percent, and the anemia drug Procrit, which fell by 37 percent.

Also during the quarter, the company announced that it received an approvable letter from the Food and Drug Administration regarding its application for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections, as well as submitting an application to the FDA for tapentadol hydrochloride immediate release tablets, an investigational oral analgesic for the relief of moderate to severe acute pain.

“We achieved solid earnings in the first quarter which reflects our continued focus on profitable growth for Johnson & Johnson,” said William Weldon, chairman and chief executive officer. “Our strategy of being broadly based remains one of the keys to our consistent long-term performance.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Perrigo gets FDA approval for generic OTC Zyrtec

BY Michael Johnsen

ALLEGAN, Mich. Perrigo earlier this week received final approval from the Food and Drug Administration to manufacture and market over-the-counter store-brand equivalents to McNeil Consumer’s Children’s Zyrtec oral solution, indicated for indoor and outdoor allergy and hives relief.

According to Wolters Kluwer data, brand sales for the original prescription strength version of the product for the last 12 months ending December 2007 were approximately $80 million.

Perrigo expects to begin shipping the product immediately.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?